DoctoRx Unscripted

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for Part 2 of this DoctoRx Unscripted conversation exploring how biology-based behavior change is redefining cancer care. In Part 2, Dr. Small hosts Arianna Huffington, Founder and CEO of Thrive Global, and Chris Boerner, Board Chair and CEO of Bristol Myers Squibb, for a candid discussion on moving beyond treating the tumor to delivering true whole-person care. Together, they explore: How everyday factors, like sleep, stress, movement, and social connection, impact cancer care Simple steps to reinforce healthier daily routines Why lifestyle changes remain critical alongside medical therapies How pharma leaders can integrate behavioral metrics into clinical trials Strategies to overcome healthcare disparities and expand access to behavioral health tools   Medicines and healthy behaviors achieve more together than either can alone. Tune in to see why placing the patient at the center of oncology care can drive better long-term outcomes.

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for Part 1 of a timely DoctoRx Unscripted conversation with Dr. Neil Iyengar, board-certified medical oncologist and Director of Survivorship Services at Winship Cancer Institute of Emory University. Together, they examine how metabolism, body composition, the gut microbiome, stress, and sleep influence cancer risk, treatment response, and long-term survivorship. In this episode, Dr. Small and Dr. Iyengar discuss: Why muscle-to-fat ratio matters more than BMI for health and cancer risk The connection between gut health, fiber, and cancer treatment success What new research reveals about GLP-1s in oncology How clinicians can make tailored exercise and nutrition accessible to every patient   Learn how targeted lifestyle interventions pair with precision oncology.

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a forward-looking episode of DoctoRx Unscripted, featuring leading thoracic oncologists Dr. Christine Lovly and Dr. Nate Pennell. Together, they examine innovations redefining what’s possible for patients with lung cancer: Biomarker-driven therapy and molecular profiling; Liquid biopsy and ctDNA testing; AI-assisted detection and radiomics; and Next-generation immunotherapies, including bispecifics, T-cell engagers, and personalized vaccines. They also share their perspectives on a critical challenge: translating scientific progress into real-world impact by expanding access and closing gaps in care. If you're working to advance oncology care—or interested in deepening your understanding of what’s shaping its future—this is a conversation you don’t want to miss.

Part 3 - The Movement Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.    In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world.    The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.  

Part 2 - The Shift Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.    In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why HCM has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory.    The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.